![Cindy Fevre](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Cindy Fevre is currently the Chief Scientific Officer at PHAXIAM Therapeutics SA since 2023.
Previously, she worked as a Research Director at Pherecydes Pharma SA. She holds a doctorate degree from the Pasteur Institute.
| Companies | Position | Start |
|---|---|---|
| PHAXIAM THERAPEUTICS S.A. | Chief Tech/Sci/R&D Officer | 23/06/2023 |
| Companies | Position | End |
|---|---|---|
| PHERECYDES PHARMA | Chief Tech/Sci/R&D Officer | - |
Active
Inactive
Listed companies
Private companies
| Private companies | 3 |
|---|---|
Pherecydes Pharma SA
 Pherecydes Pharma SA Pharmaceuticals: MajorHealth Technology Specializes in nano technologies for pharmaceutical purposes | Health Technology |
Pasteur Institute
 Pasteur Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PHAXIAM Therapeutics SA
 PHAXIAM Therapeutics SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops red blood cell-based therapeutics for severe forms of cancer & orphan diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions
